Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2024

Open Access 01-12-2024 | Gastric Cancer | Review

Unveiling the gastric microbiota: implications for gastric carcinogenesis, immune responses, and clinical prospects

Authors: Zhiyi Liu, Dachuan Zhang, Siyu Chen

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2024

Login to get access

Abstract

High-throughput sequencing has ushered in a paradigm shift in gastric microbiota, breaking the stereotype that the stomach is hostile to microorganisms beyond H. pylori. Recent attention directed toward the composition and functionality of this 'community' has shed light on its potential relevance in cancer. The microbial composition in the stomach of health displays host specificity which changes throughout a person's lifespan and is subject to both external and internal factors. Distinctive alterations in gastric microbiome signature are discernible at different stages of gastric precancerous lesions and malignancy. The robust microbes that dominate in gastric malignant tissue are intricately implicated in gastric cancer susceptibility, carcinogenesis, and the modulation of immunosurveillance and immune escape. These revelations offer fresh avenues for utilizing gastric microbiota as predictive biomarkers in clinical settings. Furthermore, inter-individual microbiota variations partially account for differential responses to cancer immunotherapy. In this review, we summarize current literature on the influence of the gastric microbiota on gastric carcinogenesis, anti-tumor immunity and immunotherapy, providing insights into potential clinical applications.
Literature
1.
Ajani JA, D’Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(2):167–92.PubMedCrossRef
2.
Thrift AP, Wenker TN, El-Serag HB. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. Nat Rev Clin Oncol. 2023;20(5):338–49.PubMedCrossRef
3.
4.
Malfertheiner P, Camargo MC, El-Omar E, Liou JM, Peek R, Schulz C, et al. Helicobacter pylori infection. Nat Rev Dis Primer. 2023;9(1):1–24.CrossRef
5.
Yeoh KG, Tan P. Mapping the genomic diaspora of gastric cancer. Nat Rev Cancer. 2022;22(2):71–84.PubMedCrossRef
6.
Yin J, Wu X, Li S, Li C, Guo Z. Impact of environmental factors on gastric cancer: a review of the scientific evidence, human prevention and adaptation. J Environ Sci. 2020;89:65–79.CrossRef
7.
Asaka M, Kobayashi M, Kudo T, Akino K, Asaka Y, Fujimori K, et al. Gastric cancer deaths by age group in Japan: outlook on preventive measures for elderly adults. Cancer Sci. 2020;111(10):3845–53.PubMedPubMedCentralCrossRef
8.
9.
Gunathilake MN, Lee J, Choi IJ, Kim YI, Ahn Y, Park C, et al. Association between the relative abundance of gastric microbiota and the risk of gastric cancer: a case-control study. Sci Rep. 2019;9(1):13589.PubMedPubMedCentralCrossRef
10.
Chen BY, Lin WZ, Li YL, Bi C, Du LJ, Liu Y, et al. Roles of oral microbiota and oral-gut microbial transmission in hypertension. J Adv Res. 2023;43:147–61.PubMedCrossRef
11.
Zmora N, Suez J, Elinav E. You are what you eat: diet, health and the gut microbiota. Nat Rev Gastroenterol Hepatol. 2019;16(1):35–56.PubMedCrossRef
12.
O’Dwyer DN, Ashley SL, Gurczynski SJ, Xia M, Wilke C, Falkowski NR, et al. Lung microbiota contribute to pulmonary inflammation and disease progression in pulmonary fibrosis. Am J Respir Crit Care Med. 2019;199(9):1127–38.PubMedPubMedCentralCrossRef
13.
Uberoi A, Bartow-McKenney C, Zheng Q, Flowers L, Campbell A, Knight SAB, et al. Commensal microbiota regulates skin barrier function and repair via signaling through the aryl hydrocarbon receptor. Cell Host Microbe. 2021;29(8):1235–1248.e8.PubMedPubMedCentralCrossRef
14.
Adu-Oppong B, Thänert R, Wallace MA, Burnham CAD, Dantas G. Substantial overlap between symptomatic and asymptomatic genitourinary microbiota states. Microbiome. 2022;10(1):6.PubMedPubMedCentralCrossRef
15.
Yachida S, Mizutani S, Shiroma H, Shiba S, Nakajima T, Sakamoto T, et al. Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. Nat Med. 2019;25(6):968–76.PubMedCrossRef
16.
Li R, Zhou R, Wang H, Li W, Pan M, Yao X, et al. Gut microbiota-stimulated cathepsin K secretion mediates TLR4-dependent M2 macrophage polarization and promotes tumor metastasis in colorectal cancer. Cell Death Differ. 2019;26(11):2447–63.PubMedPubMedCentralCrossRef
17.
Overacre-Delgoffe AE, Bumgarner HJ, Cillo AR, Burr AHP, Tometich JT, Bhattacharjee A, et al. Microbiota-specific T follicular helper cells drive tertiary lymphoid structures and anti-tumor immunity against colorectal cancer. Immunity. 2021;54(12):2812–2824.e4.PubMedPubMedCentralCrossRef
18.
Stein-Thoeringer CK, Saini NY, Zamir E, Blumenberg V, Schubert ML, Mor U, et al. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nat Med. 2023;29(4):906–16.PubMedPubMedCentralCrossRef
19.
Andrews MC, Duong CPM, Gopalakrishnan V, Iebba V, Chen WS, Derosa L, et al. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med. 2021;27(8):1432–41.PubMedCrossRef
20.
Sekirov I, Russell SL, Antunes LCM, Finlay BB. Gut microbiota in health and disease. Physiol Rev. 2010;90(3):859–904.PubMedCrossRef
21.
Abate M, Vos E, Gonen M, Janjigian YY, Schattner M, Laszkowska M, et al. A novel microbiome signature in gastric cancer: a two independent cohort retrospective analysis. Ann Surg. 2022;276(4):605–15.PubMedCrossRef
22.
Zhang X, Li C, Cao W, Zhang Z. Alterations of gastric microbiota in gastric cancer and precancerous stages. Front Cell Infect Microbiol. 2021;11:559148.PubMedPubMedCentralCrossRef
23.
Gantuya B, El Serag HB, Matsumoto T, Ajami NJ, Uchida T, Oyuntsetseg K, et al. Gastric mucosal microbiota in a Mongolian population with gastric cancer and precursor conditions. Aliment Pharmacol Ther. 2020;51(8):770–80.PubMedPubMedCentralCrossRef
24.
Monstein HJ, Tiveljung A, Kraft CH, Borch K, Jonasson J. Profiling of bacterial flora in gastric biopsies from patients with Helicobacter pylori-associated gastritis and histologically normal control individuals by temperature gradient gel electrophoresis and 16S rDNA sequence analysis. J Med Microbiol. 2000;49(9):817–22.PubMedCrossRef
25.
26.
Perkins GA, den Bakker HC, Burton AJ, Erb HN, McDonough SP, McDonough PL, et al. Equine stomachs harbor an abundant and diverse mucosal microbiota. Appl Environ Microbiol. 2012;78(8):2522–32.PubMedPubMedCentralCrossRef
27.
Narunsky-Haziza L, Sepich-Poore GD, Livyatan I, Asraf O, Martino C, Nejman D, et al. Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions. Cell. 2022;185(20):3789–3806.e17.PubMedPubMedCentralCrossRef
28.
von Rosenvinge EC, Song Y, White JR, Maddox C, Blanchard T, Fricke WF. Immune status, antibiotic medication and pH are associated with changes in the stomach fluid microbiota. ISME J. 2013;7(7):1354–66.CrossRef
29.
Wensel CR, Pluznick JL, Salzberg SL, Sears CL. Next-generation sequencing: insights to advance clinical investigations of the microbiome. J Clin Invest. 2022;132(7):e154944.PubMedPubMedCentralCrossRef
30.
Bik EM, Eckburg PB, Gill SR, Nelson KE, Purdom EA, Francois F, et al. Molecular analysis of the bacterial microbiota in the human stomach. Proc Natl Acad Sci. 2006;103(3):732–7.PubMedPubMedCentralCrossRef
31.
Bajorek S, Parker L, Li N, Winglee K, Weaver M, Johnson J, et al. Initial microbial community of the neonatal stomach immediately after birth. Gut Microbes. 2019;10(3):289–97.PubMedCrossRef
32.
Milisavljevic V, Garg M, Vuletic I, Miller JF, Kim L, Cunningham TD, et al. Prospective assessment of the gastroesophageal microbiome in VLBW neonates. BMC Pediatr. 2013;13(1):49.PubMedPubMedCentralCrossRef
33.
Moles L, Gómez M, Jiménez E, Bustos G, de Andrés J, Melgar A, et al. Bacterial diversity of the gastric content of preterm infants during their first month of life at the hospital. Front Nutr. 2017;4:4.CrossRef
34.
Patel K, Konduru K, Patra AK, Chandel DS, Panigrahi P. Trends and determinants of gastric bacterial colonization of preterm neonates in a NICU setting. Rogers LK, editor. PLoS One. 2015;10(7):e0114664.PubMedPubMedCentralCrossRef
35.
Li XX, Wong GLH, To KF, Wong VWS, Lai LH, Chow DKL, et al. Bacterial microbiota profiling in gastritis without Helicobacter pylori infection or non-steroidal anti-inflammatory drug use. PLoS ONE. 2009;4(11):e7985.PubMedPubMedCentralCrossRef
36.
Kashiwagi S, Naito Y, Inoue R, Takagi T, Nakano T, Inada Y, et al. Mucosa-associated microbiota in the gastrointestinal tract of healthy Japanese subjects. Digestion. 2020;101(2):107–20.PubMedCrossRef
37.
Ndegwa N, Ploner A, Andersson AF, Zagai U, Andreasson A, Vieth M, et al. Gastric microbiota in a low–Helicobacter pylori prevalence general population and their associations with gastric lesions. Clin Transl Gastroenterol. 2020;11(7):e00191.PubMedPubMedCentralCrossRef
38.
Vasapolli R, Schütte K, Schulz C, Vital M, Schomburg D, Pieper DH, et al. Analysis of transcriptionally active bacteria throughout the gastrointestinal tract of healthy individuals. Gastroenterology. 2019;157(4):1081–1092.e3.PubMedCrossRef
39.
Chee WJY, Chew SY, Than LTL. Vaginal microbiota and the potential of Lactobacillus derivatives in maintaining vaginal health. Microb Cell Factories. 2020;19(1):203.CrossRef
40.
Sprong KE, Mabenge M, Wright CA, Govender S. Ureaplasma species and preterm birth: current perspectives. Crit Rev Microbiol. 2020;46(2):169–81.PubMedCrossRef
41.
Zimmermann P, Curtis N. Breast milk microbiota: a review of the factors that influence composition. J Infect. 2020;81(1):17–47.PubMedCrossRef
42.
Dong Q, Xin Y, Wang L, Meng X, Yu X, Lu L, et al. Characterization of gastric microbiota in twins. Curr Microbiol. 2017;74(2):224–9.PubMedCrossRef
43.
Nyangahu DD, Lennard KS, Brown BP, Darby MG, Wendoh JM, Havyarimana E, et al. Disruption of maternal gut microbiota during gestation alters offspring microbiota and immunity. Microbiome. 2018;6(1):124.PubMedPubMedCentralCrossRef
44.
Trevisi P, Priori D, Motta V, Luise D, Jansman AJM, Koopmans SJ, et al. The effects of starter microbiota and the early life feeding of medium chain triglycerides on the gastric transcriptome profile of 2- or 3-week-old cesarean delivered piglets. J Anim Sci Biotechnol. 2017;8(1):82.PubMedPubMedCentralCrossRef
45.
Van Hul M, Cani PD. The gut microbiota in obesity and weight management: microbes as friends or foe? Nat Rev Endocrinol. 2023;19(5):258–71.PubMedCrossRef
46.
Zou Y, Ju X, Chen W, Yuan J, Wang Z, Aluko RE, et al. Rice bran attenuated obesity via alleviating dyslipidemia, browning of white adipocytes and modulating gut microbiota in high-fat diet-induced obese mice. Food Funct. 2020;11(3):2406–17.PubMedCrossRef
47.
Dapa T, Ramiro RS, Pedro MF, Gordo I, Xavier KB. Diet leaves a genetic signature in a keystone member of the gut microbiota. Cell Host Microbe. 2022;30(2):183–199.e10.PubMedCrossRef
48.
Xie Y, Pei F, Liu Y, Liu Z, Chen X, Xue D. Fecal fermentation and high-fat diet-induced obesity mouse model confirmed exopolysaccharide from Weissella cibaria PFY06 can ameliorate obesity by regulating the gut microbiota. Carbohydr Polym. 2023;318:121122.PubMedCrossRef
49.
Sedghi L, DiMassa V, Harrington A, Lynch SV, Kapila YL. The oral microbiome: role of key organisms and complex networks in oral health and disease. Periodontol 2000. 2021;87(1):107–31.PubMedPubMedCentralCrossRef
50.
Fann JCY, Chiang TH, Yen AMF, Lee YC, Wu MS, Chen HH. Personalized risk assessment for dynamic transition of gastric neoplasms. J Biomed Sci. 2018;25(1):84.PubMedPubMedCentralCrossRef
51.
Png CW, Lee WJJ, Chua SJ, Zhu F, Gastric Consortium5, Yeoh KG, et al. Mucosal microbiome associates with progression to gastric cancer. Theranostics. 2022;12(1):48–58.PubMedPubMedCentralCrossRef
52.
Wang Z, Gao X, Zeng R, Wu Q, Sun H, Wu W, et al. Changes of the gastric mucosal microbiome associated with histological stages of gastric carcinogenesis. Front Microbiol. 2020;11:997.PubMedPubMedCentralCrossRef
53.
Coker OO, Dai Z, Nie Y, Zhao G, Cao L, Nakatsu G, et al. Mucosal microbiome dysbiosis in gastric carcinogenesis. Gut. 2018;67(6):1024–32.PubMedCrossRef
54.
He C, Peng C, Shu X, Wang H, Zhu Z, Ouyang Y, et al. Convergent dysbiosis of gastric mucosa and fluid microbiome during stomach carcinogenesis. Gastric Cancer. 2022;25(5):837–49.PubMedCrossRef
55.
Hsieh YY, Tung SY, Pan HY, Yen CW, Xu HW, Lin YJ, et al. Increased abundance of Clostridium and Fusobacterium in gastric microbiota of patients with gastric cancer in Taiwan. Sci Rep. 2018;8(1):158.PubMedPubMedCentralCrossRef
56.
Wu F, Yang L, Hao Y, Zhou B, Hu J, Yang Y, et al. Oral and gastric microbiome in relation to gastric intestinal metaplasia. Int J Cancer. 2022;150(6):928–40.PubMedCrossRef
57.
Ferreira RM, Pereira-Marques J, Pinto-Ribeiro I, Costa JL, Carneiro F, Machado JC, et al. Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota. Gut. 2018;67(2):226–36.PubMedCrossRef
58.
Liu X, Shao L, Liu X, Ji F, Mei Y, Cheng Y, et al. Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer. EBioMedicine. 2019;40:336–48.PubMedCrossRef
59.
Mannion A, Sheh A, Shen Z, Dzink-Fox J, Piazuelo MB, Wilson KT, et al. Shotgun metagenomics of gastric biopsies reveals compositional and functional microbiome shifts in high- and low-gastric-cancer-risk populations from Colombia, South America. Gut Microbes. 2023;15(1):2186677.PubMedPubMedCentralCrossRef
60.
Lehr K, Nikitina D, Vilchez-Vargas R, Steponaitiene R, Thon C, Skieceviciene J, et al. Microbial composition of tumorous and adjacent gastric tissue is associated with prognosis of gastric cancer. Sci Rep. 2023;13(1):4640.PubMedPubMedCentralCrossRef
61.
Chen XH, Wang A, Chu AN, Gong YH, Yuan Y. Mucosa-associated microbiota in gastric cancer tissues compared with non-cancer tissues. Front Microbiol. 2019;10:1261.PubMedPubMedCentralCrossRef
62.
Deng Y, Ding X, Song Q, Zhao G, Han L, Ding B, et al. Alterations in mucosa-associated microbiota in the stomach of patients with gastric cancer. Cell Oncol. 2021;44(3):701–14.CrossRef
63.
Wu ZF, Zou K, Wu GN, Jin ZJ, Xiang CJ, Xu S, et al. A comparison of tumor-associated and non-tumor-associated gastric microbiota in gastric cancer patients. Dig Dis Sci. 2021;66(5):1673–82.PubMedCrossRef
64.
Dai D, Yang Y, Yu J, Dang T, Qin W, Teng L, et al. Interactions between gastric microbiota and metabolites in gastric cancer. Cell Death Dis. 2021;12(12):1104.PubMedPubMedCentralCrossRef
65.
Peng R, Liu S, You W, Huang Y, Hu C, Gao Y, et al. Gastric microbiome alterations are associated with decreased CD8 + tissue-resident memory T cells in the tumor microenvironment of gastric cancer. Cancer Immunol Res. 2022;10(10):1224–40.PubMedCrossRef
66.
Yang Y, Dai D, Jin W, Huang Y, Zhang Y, Chen Y, et al. Microbiota and metabolites alterations in proximal and distal gastric cancer patients. J Transl Med. 2022;20(1):439.PubMedPubMedCentralCrossRef
67.
Xi J, Li Y, Zhang H, Bai Z. Dynamic variations of the gastric microbiota: key therapeutic points in the reversal of Correa’s cascade. Int J Cancer. 2023;152(6):1069–84.PubMedCrossRef
68.
Yan L, Chen Y, Chen F, Tao T, Hu Z, Wang J, et al. Effect of Helicobacter pylori eradication on gastric cancer prevention: updated report from a randomized controlled trial with 26.5 years of follow-up. Gastroenterology. 2022;163(1):154–162.e3.PubMedCrossRef
69.
Liou JM, Malfertheiner P, Lee YC, Sheu BS, Sugano K, Cheng HC, et al. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut. 2020;69(12):2093–112.PubMedCrossRef
70.
Sung JJY, Coker OO, Chu E, Szeto CH, Luk STY, Lau HCH, et al. Gastric microbes associated with gastric inflammation, atrophy and intestinal metaplasia 1 year after Helicobacter pylori eradication. Gut. 2020;69(9):1572–81.PubMedCrossRef
71.
Boehm ET, Thon C, Kupcinskas J, Steponaitiene R, Skieceviciene J, Canbay A, et al. Fusobacterium nucleatum is associated with worse prognosis in Lauren’s diffuse type gastric cancer patients. Sci Rep. 2020;10(1):16240.PubMedPubMedCentralCrossRef
72.
Hsieh YY, Tung SY, Pan HY, Chang TS, Wei KL, Chen WM, et al. Fusobacterium nucleatum colonization is associated with decreased survival of helicobacter pylori-positive gastric cancer patients. World J Gastroenterol. 2021;27(42):7311–23.PubMedPubMedCentralCrossRef
73.
Guan SW, Lin Q, Wu XD, Yu HB. Weighted gene coexpression network analysis and machine learning reveal oncogenome associated microbiome plays an important role in tumor immunity and prognosis in pan-cancer. J Transl Med. 2023;21:537.PubMedPubMedCentralCrossRef
74.
Yang J, Xu J, Ling Z, Zhou X, Si Y, Liu X, et al. Prognostic effects of the gastric mucosal microbiota in gastric cancer. Cancer Sci. 2023;114(3):1075–85.PubMedCrossRef
75.
Nasr R, Shamseddine A, Mukherji D, Nassar F, Temraz S. The crosstalk between microbiome and immune response in gastric cancer. Int J Mol Sci. 2020;21(18):6586.PubMedPubMedCentralCrossRef
76.
He J, Hu W, Ouyang Q, Zhang S, He L, Chen W, et al. Helicobacter pylori infection induces stem cell-like properties in Correa cascade of gastric cancer. Cancer Lett. 2022;542:215764.PubMedCrossRef
77.
Chauhan N, Tay ACY, Marshall BJ, Jain U. Helicobacter pylori VacA, a distinct toxin exerts diverse functionalities in numerous cells: an overview. Helicobacter. 2019;24(1):e12544.PubMedCrossRef
78.
Toh JWT, Wilson RB. Pathways of gastric carcinogenesis, Helicobacter pylori virulence and interactions with antioxidant systems, vitamin C and phytochemicals. Int J Mol Sci. 2020;21(17):6451.PubMedPubMedCentralCrossRef
79.
Zhang X, Soutto M, Chen Z, Bhat N, Zhu S, Eissmann MF, et al. Induction of fibroblast growth factor receptor 4 by Helicobacter pylori via signal transducer and activator of transcription 3 with a feedforward activation loop involving steroid receptor coactivator signaling in gastric cancer. Gastroenterology. 2022;163(3):620–636.e9.PubMedCrossRef
80.
Wang Z, Shan Y, Wang R, Zhou H, Hu R, Li Y, et al. Structural insights into the binding propensity of human SHIP2 SH2 to oncogenic CagA isoforms from Helicobacter pylori. Int J Mol Sci. 2022;23(19):11299.PubMedPubMedCentralCrossRef
81.
Murata-Kamiya N, Kurashima Y, Teishikata Y, Yamahashi Y, Saito Y, Higashi H, et al. Helicobacter pylori CagA interacts with E-cadherin and deregulates the beta-catenin signal that promotes intestinal transdifferentiation in gastric epithelial cells. Oncogene. 2007;26(32):4617–26.PubMedCrossRef
82.
Saadat I, Higashi H, Obuse C, Umeda M, Murata-Kamiya N, Saito Y, et al. Helicobacter pylori CagA targets PAR1/MARK kinase to disrupt epithelial cell polarity. Nature. 2007;447(7142):330–3.PubMedCrossRef
83.
Imai S, Ooki T, Murata-Kamiya N, Komura D, Tahmina K, Wu W, et al. Helicobacter pylori CagA elicits BRCAness to induce genome instability that may underlie bacterial gastric carcinogenesis. Cell Host Microbe. 2021;29(6):941–958.e10.PubMedCrossRef
84.
Saha A, Backert S, Hammond CE, Gooz M, Smolka AJ. Helicobacter pylori CagL activates ADAM17 to induce repression of the gastric H, K-ATPase α subunit. Gastroenterology. 2010;139(1):239–48.PubMedCrossRef
85.
Yao X, Smolka AJ. Gastric parietal cell physiology and Helicobacter pylori–induced disease. Gastroenterology. 2019;156(8):2158–73.PubMedCrossRef
86.
Skinner GR. Transformation of primary hamster embryo fibroblasts by type 2 simplex virus: evidence for a “hit and run” mechanism. Br J Exp Pathol. 1976;57(4):361–76.PubMedPubMedCentral
87.
Hatakeyama M. Helicobacter pylori CagA and gastric cancer: a paradigm for hit-and-run carcinogenesis. Cell Host Microbe. 2014;15(3):306–16.PubMedCrossRef
88.
Gantuya B, El-Serag HB, Matsumoto T, Ajami NJ, Oyuntsetseg K, Azzaya D, et al. Gastric microbiota in Helicobacter pylori-negative and -positive gastritis among high incidence of gastric cancer area. Cancers. 2019;11(4):504.PubMedPubMedCentralCrossRef
89.
Miftahussurur M, Waskito LA, El-Serag HB, Ajami NJ, Nusi IA, Syam AF, et al. Gastric microbiota and Helicobacter pylori in Indonesian population. Helicobacter. 2020;25(4):e12695.PubMedCrossRef
90.
Llorca L, Pérez-Pérez G, Urruzuno P, Martinez MJ, Iizumi T, Gao Z, et al. Characterization of the gastric microbiota in a pediatric population according to Helicobacter pylori status. Pediatr Infect Dis J. 2017;36(2):173–8.PubMedCrossRef
91.
Guo Y, Zhang Y, Gerhard M, Gao JJ, Mejias-Luque R, Zhang L, et al. Effect of Helicobacter pylori on gastrointestinal microbiota: a population-based study in Linqu, a high-risk area of gastric cancer. Gut. 2020;69(9):1598–607.PubMedCrossRef
92.
Miao R, Wan C, Wang Z. The relationship of gastric microbiota and Helicobacter pylori infection in pediatrics population. Helicobacter. 2020;25(1):e12676.PubMedCrossRef
93.
Klymiuk I, Bilgilier C, Stadlmann A, Thannesberger J, Kastner MT, Högenauer C, et al. The human gastric microbiome is predicated upon infection with Helicobacter pylori. Front Microbiol. 2017;8:2508.PubMedPubMedCentralCrossRef
94.
Lofgren JL, Whary MT, Ge Z, Muthupalani S, Taylor NS, Mobley M, et al. Lack of commensal flora in Helicobacter pylori–Infected INS-GAS mice reduces gastritis and delays intraepithelial neoplasia. Gastroenterology. 2011;140(1):210–220.e4.PubMedCrossRef
95.
Lertpiriyapong K, Whary MT, Muthupalani S, Lofgren JL, Gamazon ER, Feng Y, et al. Gastric colonisation with a restricted commensal microbiota replicates the promotion of neoplastic lesions by diverse intestinal microbiota in the Helicobacter pylori INS-GAS mouse model of gastric carcinogenesis. Gut. 2014;63(1):54–63.PubMedCrossRef
96.
Shen Z, Dzink-Fox J, Feng Y, Muthupalani S, Mannion AJ, Sheh A, et al. Gastric non-Helicobacter pylori urease-positive Staphylococcus epidermidis and Streptococcus salivarius isolated from humans have contrasting effects on H. pylori-associated gastric pathology and host immune responses in a murine model of gastric cancer. Young VB, editor. mSphere. 2022;7(1):e00772–21.PubMedPubMedCentralCrossRef
97.
Chen Z, Tang Z, Li W, Deng X, Yu L, Yang J, et al. Weizmannia coagulans BCF-01: a novel gastrogenic probiotic for Helicobacter pylori infection control. Gut Microbes. 2024;16(1):2313770.
98.
Gebremariam HG, Qazi KR, Somiah T, Pathak SK, Sjölinder H, Sverremark Ekström E, et al. Lactobacillus gasseri suppresses the production of proinflammatory cytokines in Helicobacter pylori-infected macrophages by inhibiting the expression of ADAM17. Front Immunol. 2019;10:2326.PubMedPubMedCentralCrossRef
99.
Shen S, Ren F, Qin H, Bukhari I, Yang J, Gao D, et al. Lactobacillus acidophilus NCFM and Lactiplantibacillus plantarum Lp-115 inhibit Helicobacter pylori colonization and gastric inflammation in a murine model. Front Cell Infect Microbiol. 2023;13:1196084.PubMedPubMedCentralCrossRef
100.
Khosravi Y, Loke MF, Goh KL, Vadivelu J. Proteomics analysis revealed that crosstalk between Helicobacter pylori and Streptococcus mitis may enhance bacterial survival and reduces carcinogenesis. Front Microbiol. 2016;7:7.CrossRef
101.
Khosravi Y, Dieye Y, Loke MF, Goh KL, Vadivelu J. Streptococcus mitis induces conversion of Helicobacter pylori to coccoid cells during co-culture in vitro. PLoS ONE. 2014;9(11):e112214.PubMedPubMedCentralCrossRef
102.
Chen Z, Tang Z, Li W, Deng X, Yu L, Yang J, et al. Weizmannia coagulans BCF-01: a novel gastrogenic probiotic for Helicobacter pylori infection control. Gut Microbes. 2024;16(1):2313770.PubMedPubMedCentralCrossRef
103.
Kwon SK, Park JC, Kim KH, Yoon J, Cho Y, Lee B, et al. Human gastric microbiota transplantation recapitulates premalignant lesions in germ-free mice. Gut. 2022;71(7):1266–76.PubMedCrossRef
104.
Sasaki M, Kodama Y, Shimoyama Y, Ishikawa T, Kimura S. Aciduricity and acid tolerance mechanisms of Streptococcus anginosus. J Gen Appl Microbiol. 2018;64(4):174–9.PubMedCrossRef
105.
Fu K, Cheung AHK, Wong CC, Liu W, Zhou Y, Wang F, et al. Streptococcus anginosus promotes gastric inflammation, atrophy, and tumorigenesis in mice. Cell. 2024;187(4):882–896.e17.PubMedCrossRef
106.
Li Y, Huang X, Tong D, Jiang C, Zhu X, Wei Z, et al. Relationships among microbiota, gastric cancer, and immunotherapy. Front Microbiol. 2022;13:987763.PubMedPubMedCentralCrossRef
107.
Vinasco K, Mitchell HM, Kaakoush NO, Castaño-Rodríguez N. Microbial carcinogenesis: lactic acid bacteria in gastric cancer. Biochim Biophys Acta BBA - Rev Cancer. 2019;1872(2):188309.CrossRef
108.
Hwang CH, Lee NK, Paik HD. The anti-cancer potential of heat-killed Lactobacillus brevis KU15176 upon AGS Cell lines through intrinsic apoptosis pathway. Int J Mol Sci. 2022;23(8):4073.PubMedPubMedCentralCrossRef
109.
Chen MJ, Chen CC, Huang YC, Tseng CC, Hsu JT, Lin YF, et al. The efficacy of Lactobacillus acidophilus and rhamnosus in the reduction of bacterial load of Helicobacter pylori and modification of gut microbiota-a double-blind, placebo-controlled, randomized trial. Helicobacter. 2021;26(6):e12857.PubMedCrossRef
110.
Zhao Y, Li Z, Zhao L, Wang J, Wang F, Zhang Q, et al. Two novel lactic acid bacteria, limosilactobacillus fermentum MN-LF23 and Lactobacillus gasseri MN-LG80, inhibited Helicobacter pylori infection in C57BL/6 mice. Food Funct. 2022;13(21):11061–9.PubMedCrossRef
111.
Delgado S, Leite AMO, Ruas-Madiedo P, Mayo B. Probiotic and technological properties of Lactobacillus spp. strains from the human stomach in the search for potential candidates against gastric microbial dysbiosis. Front Microbiol. 2015;5:5.CrossRef
112.
Xu Z, Xiao L, Wang S, Cheng Y, Wu J, Meng Y, et al. Alteration of gastric microbiota and transcriptome in a rat with gastric intestinal metaplasia induced by deoxycholic acid. Front Microbiol. 2023;14:1160821.PubMedPubMedCentralCrossRef
113.
Jin D, Huang K, Xu M, Hua H, Ye F, Yan J, et al. Deoxycholic acid induces gastric intestinal metaplasia by activating STAT3 signaling and disturbing gastric bile acids metabolism and microbiota. Gut Microbes. 2022;14(1):2120744.PubMedPubMedCentralCrossRef
114.
Wang S, Kuang J, Zhang H, Chen W, Zheng X, Wang J, et al. Bile acid–microbiome interaction promotes gastric carcinogenesis. Adv Sci. 2022;9(16):2200263.CrossRef
115.
Gunathilake M, Lee J, Choi IJ, Kim YI, Yoon J, Sul WJ, et al. Alterations in gastric microbial communities are associated with risk of gastric cancer in a Korean population: a case-control study. Cancers. 2020;12(9):2619.PubMedPubMedCentralCrossRef
116.
Seyyedsalehi MS, Mohebbi E, Tourang F, Sasanfar B, Boffetta P, Zendehdel K. Association of dietary nitrate, nitrite, and N-Nitroso compounds Intake and gastrointestinal cancers: a systematic review and meta-analysis. Toxics. 2023;11(2):190.PubMedPubMedCentralCrossRef
117.
Kraus A, McKeague M, Seiwert N, Nagel G, Geisen SM, Ziegler N, et al. Immunological and mass spectrometry-based approaches to determine thresholds of the mutagenic DNA adduct O6-methylguanine in vivo. Arch Toxicol. 2019;93(2):559–72.PubMedCrossRef
118.
Oosterlinck B, Ceuleers H, Arras W, De Man JG, Geboes K, De Schepper H, et al. Mucin-microbiome signatures shape the tumor microenvironment in gastric cancer. Microbiome. 2023;11(1):86.PubMedPubMedCentralCrossRef
119.
Shimamura T, Ito H, Shibahara J, Watanabe A, Hippo Y, Taniguchi H, et al. Overexpression of MUC13 is associated with intestinal-type gastric cancer. Cancer Sci. 2005;96(5):265–73.PubMedCrossRef
120.
Sheng YH, He Y, Hasnain SZ, Wang R, Tong H, Clarke DT, et al. MUC13 protects colorectal cancer cells from death by activating the NF-κB pathway and is a potential therapeutic target. Oncogene. 2017;36(5):700–13.PubMedCrossRef
121.
Tiemin P, Fanzheng M, Peng X, Jihua H, Ruipeng S, Yaliang L, et al. MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways. J Hepatol. 2020;72(4):761–73.PubMedCrossRef
122.
Cao Y, Xia H, Tan X, Shi C, Ma Y, Meng D, et al. Intratumoural microbiota: a new frontier in cancer development and therapy. Signal Transduct Target Ther. 2024;9:15.PubMedPubMedCentralCrossRef
123.
Yue K, Sheng D, Xue X, Zhao L, Zhao G, Jin C, et al. Bidirectional mediation effects between intratumoral microbiome and host DNA methylation changes contribute to stomach adenocarcinoma. Microbiol Spectr. 2023;11(4):e0090423.PubMedCrossRef
124.
125.
Xin Y, Li X, Zhang M, Shang Z, Luo Z, Wang Y, et al. Fusobacterium nucleatum -induced exosomal HOTTIP promotes gastric cancer progression through the microRNA -885-3p/ EphB2 axis. Cancer Sci. 2023;114(6):2360–74.PubMedPubMedCentralCrossRef
126.
Nie S, Wang A, Yuan Y. Comparison of clinicopathological parameters, prognosis, micro-ecological environment and metabolic function of gastric cancer with or without Fusobacterium sp. infection. J Cancer. 2021;12(4):1023–32.PubMedPubMedCentralCrossRef
127.
do Nascimento Araujo C, Amorim AT, Barbosa MS, Alexandre JCPL, Campos GB, Macedo CL, et al. Evaluating the presence of Mycoplasma hyorhinis, Fusobacterium nucleatum, and Helicobacter pylori in biopsies of patients with gastric cancer. Infect Agent Cancer. 2021;16(1):70.PubMedPubMedCentralCrossRef
128.
Parhi L, Alon-Maimon T, Sol A, Nejman D, Shhadeh A, Fainsod-Levi T, et al. Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression. Nat Commun. 2020;11(1):3259.PubMedPubMedCentralCrossRef
129.
Mereiter S, Polom K, Williams C, Polonia A, Guergova-Kuras M, Karlsson NG, et al. The Thomsen-Friedenreich antigen: a highly sensitive and specific predictor of microsatellite instability in gastric cancer. J Clin Med. 2018;7(9):256.PubMedPubMedCentralCrossRef
130.
Guo P, Tian Z, Kong X, Yang L, Shan X, Dong B, et al. FadA promotes DNA damage and progression of Fusobacterium nucleatum-induced colorectal cancer through up-regulation of chk2. J Exp Clin Cancer Res. 2020;39(1):202.PubMedPubMedCentralCrossRef
131.
Yang Y, Weng W, Peng J, Hong L, Yang L, Toiyama Y, et al. Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor − κB, and up-regulating expression of microRNA-21. Gastroenterology. 2017;152(4):851–866.e24.PubMedCrossRef
132.
Kang W, Jia Z, Tang D, Zhang Z, Gao H, He K, et al. Fusobacterium nucleatum facilitates apoptosis, ROS generation, and inflammatory cytokine production by activating AKT/MAPK and NF- κ B signaling pathways in human gingival fibroblasts. Oxid Med Cell Longev. 2019;2019:1–22.CrossRef
133.
Chen Y, Chen Y, Cao P, Su W, Zhan N, Dong W. Fusobacterium nucleatum facilitates ulcerative colitis through activating IL-17F signaling to NF‐κB via the upregulation of CARD3 expression. J Pathol. 2020;250(2):170–82.PubMedCrossRef
134.
Xu C, Fan L, Lin Y, Shen W, Qi Y, Zhang Y, et al. Fusobacterium nucleatum promotes colorectal cancer metastasis through miR-1322/CCL20 axis and M2 polarization. Gut Microbes. 2021;13(1):1980347.PubMedPubMedCentralCrossRef
135.
Kim SY, Park SY, Jang HS, Park YD, Kee SH. Yes-associated protein is required for ZO-1-mediated tight-junction integrity and cell migration in E-cadherin-restored AGS gastric cancer cells. Biomedicines. 2021;9(9):1264.PubMedPubMedCentralCrossRef
136.
Peng C, Ouyang Y, Lu N, Li N. The NF-κB signaling pathway, the microbiota, and gastrointestinal tumorigenesis: recent advances. Front Immunol. 2020;11:1387.PubMedPubMedCentralCrossRef
137.
Kim JM, Cho SJ, Oh YK, Jung HY, Kim YJ, Kim N. Nuclear factor-kappa B activation pathway in intestinal epithelial cells is a major regulator of chemokine gene expression and neutrophil migration induced by Bacteroides fragilis enterotoxin. Clin Exp Immunol. 2002;130(1):59–66.PubMedPubMedCentralCrossRef
138.
Cao L, Zhu S, Lu H, Soutto M, Bhat N, Chen Z, et al. Helicobacter pylori-induced RASAL2 through activation of NF-kB promotes gastric tumorigenesis via β-catenin signaling axis. Gastroenterology. 2022;162(6):1716–1731.e17.PubMedCrossRef
139.
Maubach G, Vieth M, Boccellato F, Naumann M. Helicobacter pylori-induced NF-κB: trailblazer for gastric pathophysiology. Trends Mol Med. 2022;28(3):210–22.PubMedCrossRef
140.
Chung L, Orberg ET, Geis AL, Chan JL, Fu K, DeStefano Shields CE, et al. Bacteroides fragilis toxin coordinates a pro-carcinogenic inflammatory cascade via targeting of colonic epithelial cells. Cell Host Microbe. 2018;23(2):203–214.e5.PubMedPubMedCentralCrossRef
141.
Long X, Wong CC, Tong L, Chu ESH, Ho Szeto C, Go MYY, et al. Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumour immunity. Nat Microbiol. 2019;4(12):2319–30.PubMedCrossRef
142.
143.
Zhong M, Xiong Y, Zhao J, Gao Z, Ma J, Wu Z, et al. Candida albicans disorder is associated with gastric carcinogenesis. Theranostics. 2021;11(10):4945–56.PubMedPubMedCentralCrossRef
144.
Dohlman AB, Klug J, Mesko M, Gao IH, Lipkin SM, Shen X, et al. A pan-cancer mycobiome analysis reveals fungal involvement in gastrointestinal and lung tumors. Cell. 2022;185(20):3807–3822.e12.PubMedPubMedCentralCrossRef
145.
Lohse MB, Gulati M, Johnson AD, Nobile CJ. Development and regulation of single- and multi-species Candida albicans biofilms. Nat Rev Microbiol. 2018;16(1):19–31.PubMedCrossRef
146.
Zhang Y, Gan Y, Wang J, Feng Z, Zhong Z, Bao H, et al. Dysbiosis of gut microbiota and intestinal barrier dysfunction in pigs with pulmonary inflammation induced by Mycoplasma hyorhinis Infection. mSystems. 2022;7(4):e00282–22.
147.
Duan H, Chen L, Qu L, Yang H, Song SW, Han Y, et al. Mycoplasma Hyorhinis infection promotes NF- κB–dependent migration of gastric cancer cells. Cancer Res. 2014;74(20):5782–94.PubMedCrossRef
148.
Morgan AD, Seely KD, Hagenstein LD, Florey GM, Small JM. Bacterial involvement in progression and metastasis of adenocarcinoma of the stomach. Cancers. 2022;14(19):4886.PubMedPubMedCentralCrossRef
149.
Xu Y, Li H, Chen W, Yao X, Xing Y, Wang X, et al. Mycoplasma hyorhinis activates the NLRP3 inflammasome and promotes migration and invasion of gastric cancer cells. PLoS ONE. 2013;8(11):e77955.PubMedPubMedCentralCrossRef
150.
Chernov AV, Reyes L, Xu Z, Gonzalez B, Golovko G, Peterson S, et al. Mycoplasma CG- and GATC-specific DNA methyltransferases selectively and efficiently methylate the host genome and alter the epigenetic landscape in human cells. Epigenetics. 2015;10(4):303–18.PubMedPubMedCentralCrossRef
151.
152.
Li Q, Wu W, Gong D, Shang R, Wang J, Yu H. Propionibacterium acnes overabundance in gastric cancer promote M2 polarization of macrophages via a TLR4/PI3K/Akt signaling. Gastric Cancer. 2021;24(6):1242–53.PubMedCrossRef
153.
Petersen CP, Meyer AR, De Salvo C, Choi E, Schlegel C, Petersen A, et al. A signalling cascade of IL-33 to IL-13 regulates metaplasia in the mouse stomach. Gut. 2018;67(5):805–17.PubMedCrossRef
154.
Satoh-Takayama N, Kato T, Motomura Y, Kageyama T, Taguchi-Atarashi N, Kinoshita-Daitoku R, et al. Bacteria-induced group 2 innate lymphoid cells in the stomach provide immune protection through induction of IgA. Immunity. 2020;52(4):635–649.e4.PubMedCrossRef
155.
Bie Q, Zhang P, Su Z, Zheng D, Ying X, Wu Y, et al. Polarization of ILC2s in peripheral blood might contribute to immunosuppressive microenvironment in patients with gastric cancer. J Immunol Res. 2014;2014:923135.PubMedPubMedCentralCrossRef
156.
Li R, Jiang XX, Zhang LF, Liu XM, Hu TZ, Xia XJ, et al. Group 2 innate lymphoid cells are involved in skewed type 2 immunity of gastric diseases induced by Helicobacter pylori infection. Mediators Inflamm. 2017;2017:4927964.PubMedPubMedCentralCrossRef
157.
158.
Hedrick CC, Malanchi I. Neutrophils in cancer: heterogeneous and multifaceted. Nat Rev Immunol. 2022;22(3):173–87.PubMedCrossRef
159.
Li TJ, Jiang YM, Hu YF, Huang L, Yu J, Zhao LY, et al. Interleukin-17–producing neutrophils link inflammatory stimuli to disease progression by promoting angiogenesis in gastric cancer. Clin Cancer Res. 2017;23(6):1575–85.PubMedCrossRef
160.
Li S, Cong X, Gao H, Lan X, Li Z, Wang W, et al. Tumor-associated neutrophils induce EMT by IL-17a to promote migration and invasion in gastric cancer cells. J Exp Clin Cancer Res. 2019;38(1):6.PubMedPubMedCentralCrossRef
161.
Nie P, Zhang W, Meng Y, Lin M, Guo F, Zhang H, et al. A YAP/TAZ-CD54 axis is required for CXCR2 − CD44 − tumor-specific neutrophils to suppress gastric cancer. Protein Cell. 2022;14(7):515–33.PubMedCentral
162.
Shan ZG, Chen J, Liu JS, Zhang JY, Wang TT, Teng YS, et al. Activated neutrophils polarize protumorigenic interleukin-17A-producing T helper subsets through TNF-α-B7-H2-dependent pathway in human gastric cancer. Clin Transl Med. 2021;11(6):e484.PubMedPubMedCentralCrossRef
163.
Chu TH, Huang ST, Yang SF, Li CJ, Lin HW, Weng BC, et al. Hepatoma-derived growth factor participates in Helicobacter Pylori-induced neutrophils recruitment, gastritis and gastric carcinogenesis. Oncogene. 2019;38(37):6461–77.PubMedCrossRef
164.
Zhang Y, Chandra V, Riquelme Sanchez E, Dutta P, Quesada PR, Rakoski A, et al. Interleukin-17–induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer. J Exp Med. 2020;217(12):e20190354.PubMedPubMedCentralCrossRef
165.
Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland K, Hau CS, et al. IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 2015;522(7556):345–8.PubMedPubMedCentralCrossRef
166.
Zhang T, Li Y, Chen J, Liu Y, Huang Z, Xu X, et al. IDDF2023-ABS-0058 Fusobacterium nucleatum intracellular parasitism activates the NF-KB/IL-17 signaling pathway induce neutrophil recruitment and promote gastric cancer progression. Gut. 2023;72(Suppl 1):A70.
167.
Ling Z, Shao L, Liu X, Cheng Y, Yan C, Mei Y, et al. Regulatory T cells and plasmacytoid dendritic cells within the tumor microenvironment in gastric cancer are correlated with gastric microbiota dysbiosis: a preliminary study. Front Immunol. 2019;10:533.PubMedPubMedCentralCrossRef
168.
169.
Liu W, Zhao J, Li Q, Wang Q, Zhou Y, Tong Z. Gastric cancer patients have elevated plasmacytoid and CD1c+ dendritic cells in the peripheral blood. Oncol Lett. 2018;15(4):5087–92.PubMedPubMedCentral
170.
Gur C, Ibrahim Y, Isaacson B, Yamin R, Abed J, Gamliel M, et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity. 2015;42(2):344–55.PubMedPubMedCentralCrossRef
171.
Dutta A, Venkataganesh H, Love PE. New insights into epigenetic regulation of T cell differentiation. Cells. 2021;10(12):533.CrossRef
172.
173.
174.
Lin R, Zhang H, Yuan Y, He Q, Zhou J, Li S, et al. Fatty acid oxidation controls CD8 + tissue-resident memory T-cell survival in gastric adenocarcinoma. Cancer Immunol Res. 2020;8(4):479–92.PubMedCrossRef
175.
Aydın EM, Demir TD, Seymen N, Said SS, Oktem-Okullu S, Tiftikci A, et al. The crosstalk between H. pylori virulence factors and the PD1:PD-L1 immune checkpoint inhibitors in progression to gastric cancer. Immunol Lett. 2021;239:1–11.PubMedCrossRef
176.
Holokai L, Chakrabarti J, Broda T, Chang J, Hawkins JA, Sundaram N, et al. Increased programmed death-ligand 1 is an early epithelial cell response to Helicobacter pylori infection. Blanke SR, editor. PLOS Pathog. 2019;15(1):e1007468.PubMedPubMedCentralCrossRef
177.
Koh V, Chakrabarti J, Torvund M, Steele N, Hawkins JA, Ito Y, et al. Hedgehog transcriptional effector GLI mediates mTOR-Induced PD-L1 expression in gastric cancer organoids. Cancer Lett. 2021;518:59–71.PubMedPubMedCentralCrossRef
178.
Li C, Jiang P, Wei S, Xu X, Wang J. Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects. Mol Cancer. 2020;19(1):116.PubMedPubMedCentralCrossRef
179.
Urakawa S, Yamasaki M, Makino T, Kurokawa Y, Yamamoto K, Goto K, et al. The impact of ICOS + regulatory T cells and Helicobacter pylori infection on the prognosis of patients with gastric and colorectal cancer: potential prognostic benefit of pre-operative eradication therapy. Cancer Immunol Immunother. 2021;70(2):443–52.PubMedCrossRef
180.
Nagase H, Takeoka T, Urakawa S, Morimoto-Okazawa A, Kawashima A, Iwahori K, et al. ICOS + Foxp3 + TILs in gastric cancer are prognostic markers and effector regulatory T cells associated with H elicobacter pylori: unique expression of ICOS on TREGS in gastric cancer. Int J Cancer. 2017;140(3):686–95.PubMedCrossRef
181.
Engelhard V, Conejo-Garcia JR, Ahmed R, Nelson BH, Willard-Gallo K, Bruno TC, et al. B cells and cancer. Cancer Cell. 2021;39(10):1293–6.PubMedCrossRef
182.
Li H, Limenitakis JP, Greiff V, Yilmaz B, Schären O, Urbaniak C, et al. Mucosal or systemic microbiota exposures shape the B cell repertoire. Nature. 2020;584(7820):274–8.PubMedCrossRef
183.
Catalán D, Mansilla MA, Ferrier A, Soto L, Oleinika K, Aguillón JC, et al. Immunosuppressive mechanisms of regulatory B cells. Front Immunol. 2021;12:611795.PubMedPubMedCentralCrossRef
184.
Horii M, Matsushita T. Regulatory B cells and T cell regulation in cancer. J Mol Biol. 2021;433(1):166685.PubMedCrossRef
185.
Nahid-Samiei M, Rahimian G, Shafigh M, Taheri F, Karami-Hurestani M, Sanaei MJ, et al. Enhanced frequency of CD19 + IL-10 + B cells in human gastric mucosa infected by Helicobacter pylori. Am J Med Sci. 2020;359(6):347–53.PubMedCrossRef
186.
187.
188.
Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy. Science. 2015;350(6264):1084–9.PubMedPubMedCentralCrossRef
189.
Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350(6264):1079–84.PubMedPubMedCentralCrossRef
190.
Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science. 2018;359(6371):91–7.PubMedCrossRef
191.
Si W, Liang H, Bugno J, Xu Q, Ding X, Yang K, et al. Lactobacillus rhamnosus GG induces cGAS/STING- dependent type I interferon and improves response to immune checkpoint blockade. Gut. 2022;71(3):521–33.PubMedCrossRef
192.
Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97–103.PubMedCrossRef
193.
Lee SH, Cho SY, Yoon Y, Park C, Sohn J, Jeong JJ, et al. Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice. Nat Microbiol. 2021;6(3):277–88.PubMedCrossRef
194.
Newsome RC, Gharaibeh RZ, Pierce CM, da Silva WV, Paul S, Hogue SR, et al. Interaction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade in a United States cohort. Genome Med. 2022;14(1):35.PubMedPubMedCentralCrossRef
195.
Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol off J Eur Soc Med Oncol. 2019;30(12):2012.CrossRef
196.
Hakozaki T, Richard C, Elkrief A, Hosomi Y, Benlaïfaoui M, Mimpen I, et al. The gut microbiome associates with immune checkpoint inhibition outcomes in patients with advanced non-small cell lung cancer. Cancer Immunol Res. 2020;8(10):1243–50.PubMedCrossRef
197.
Mao J, Wang D, Long J, Yang X, Lin J, Song Y, et al. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers. J Immunother Cancer. 2021;9(12):e003334.PubMedPubMedCentralCrossRef
198.
McCulloch JA, Davar D, Rodrigues RR, Badger JH, Fang JR, Cole AM, et al. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. Nat Med. 2022;28(3):545–56.PubMedPubMedCentralCrossRef
199.
Peng Z, Cheng S, Kou Y, Wang Z, Jin R, Hu H, et al. The gut microbiome is associated with clinical response to Anti–PD-1/PD-L1 immunotherapy in gastrointestinal cancer. Cancer Immunol Res. 2020;8(10):1251–61.PubMedCrossRef
200.
Oster P, Vaillant L, Riva E, McMillan B, Begka C, Truntzer C, et al. Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies. Gut. 2022;71(3):457–66.PubMedCrossRef
201.
Che H, Xiong Q, Ma J, Chen S, Wu H, Xu H, et al. Association of Helicobacter pylori infection with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors. BMC Cancer. 2022;22(1):904.PubMedPubMedCentralCrossRef
202.
Tonneau M, Nolin-Lapalme A, Kazandjian S, Auclin E, Panasci J, Benlaifaoui M, et al. Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors. Oncoimmunology. 2022;11(1):2096535.PubMedPubMedCentralCrossRef
203.
Derosa L, Routy B, Fidelle M, Iebba V, Alla L, Pasolli E, et al. Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients. Eur Urol. 2020;78(2):195–206.PubMedCrossRef
204.
Pinato DJ, Howlett S, Ottaviani D, Urus H, Patel A, Mineo T, et al. Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol. 2019;5(12):1774–8.PubMedPubMedCentralCrossRef
205.
Ahmed J, Kumar A, Parikh K, Anwar A, Knoll BM, Puccio C, et al. Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors. Oncoimmunology. 2018;7(11):e1507670.PubMedPubMedCentralCrossRef
206.
Hsu PI, Pan CY, Kao JY, Tsay FW, Peng NJ, Kao SS, et al. Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of proteobacteria and decreased relative abundances of bacteroidetes and actinobacteria. Helicobacter. 2018;23(4):e12498.PubMedCrossRef
207.
Schulz C, Schütte K, Koch N, Vilchez-Vargas R, Wos-Oxley ML, Oxley APA, et al. The active bacterial assemblages of the upper GI tract in individuals with and without Helicobacter infection. Gut. 2018;67(2):216–25.PubMedCrossRef
208.
Olekhnovich EI, Manolov AI, Samoilov AE, Prianichnikov NA, Malakhova MV, Tyakht AV, et al. Shifts in the human gut microbiota structure caused by quadruple Helicobacter pylori eradication therapy. Front Microbiol. 2019;10:1902.PubMedPubMedCentralCrossRef
209.
Kakiuchi T, Mizoe A, Yamamoto K, Imamura I, Hashiguchi K, Kawakubo H, et al. Effect of probiotics during vonoprazan-containing triple therapy on gut microbiota in Helicobacter pylori infection: a randomized controlled trial. Helicobacter. 2020;25(3):e12690.PubMedCrossRef
210.
Liou JM, Chen CC, Chang CM, Fang YJ, Bair MJ, Chen PY, et al. Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial. Lancet Infect Dis. 2019;19(10):1109–20.PubMedCrossRef
211.
Lurienne L, Cervesi J, Duhalde L, de Gunzburg J, Andremont A, Zalcman G, et al. NSCLC immunotherapy efficacy and antibiotic use: a systematic review and meta-analysis. J Thorac Oncol. 2020;15(7):1147–59.PubMedCrossRef
212.
Iankov ID, Allen C, Federspiel MJ, Myers RM, Peng KW, Ingle JN, et al. Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus. Mol Ther. 2012;20(6):1139–47.PubMedPubMedCentralCrossRef
213.
Ma J, Jin C, Čančer M, Wang H, Ramachandran M, Yu D. Concurrent expression of HP-NAP enhances antitumor efficacy of oncolytic vaccinia virus but not for Semliki Forest virus. Mol Ther - Oncolytics. 2021;21:356–66.PubMedPubMedCentralCrossRef
214.
Jin C, Ma J, Ramachandran M, Yu D, Essand M. CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers. Nat Biomed Eng. 2022;6(7):830–41.PubMedPubMedCentralCrossRef
215.
Xue LJ, Mao XB, Liu XB, Gao H, Chen YN, Dai TT, et al. Activation of CD3 + T cells by Helicobacter pylori DNA vaccines in potential immunotherapy of gastric carcinoma. Cancer Biol Ther. 2019;20(6):866–76.PubMedPubMedCentralCrossRef
216.
217.
Ramachandran M, Jin C, Yu D, Eriksson F, Essand M. Correction: Vector-encoded Helicobacter pylori neutrophil-activating protein promotes maturation of dendritic cells with Th1 polarization and improved migration. J Immunol Baltim Md 1950. 2015;194(11):5568.
218.
Codolo G, Facchinello N, Papa N, Bertocco A, Coletta S, Benna C, et al. Macrophage-mediated melanoma reduction after HP-NAP treatment in a zebrafish xenograft model. Int J Mol Sci. 2022;23(3):1644.PubMedPubMedCentralCrossRef
219.
Codolo G, Fassan M, Munari F, Volpe A, Bassi P, Rugge M, et al. HP-NAP inhibits the growth of bladder cancer in mice by activating a cytotoxic Th1 response. Cancer Immunol Immunother. 2012;61(1):31–40.PubMedCrossRef
220.
Wang T, Liu X, Ji Z, Men Y, Du M, Ding C, et al. Antitumor and immunomodulatory effects of recombinant fusion protein rMBP-NAP through TLR-2 dependent mechanism in tumor bearing mice. Int Immunopharmacol. 2015;29(2):876–83.PubMedCrossRef
221.
Wang T, Du M, Ji Z, Ding C, Wang C, Men Y, et al. Recombinant protein rMBP-NAP restricts tumor progression by triggering antitumor immunity in mouse metastatic lung cancer. Can J Physiol Pharmacol. 2018;96(2):113–9.PubMedCrossRef
222.
Mohabati Mobarez A, Soleimani N, Esmaeili SA, Farhangi B. Nanoparticle-based immunotherapy of breast cancer using recombinant Helicobacter pylori proteins. Eur J Pharm Biopharm. 2020;155:69–76.PubMedCrossRef
223.
Li Y, Jin Y, Zhang J, Pan H, Wu L, Liu D, et al. Recovery of human gut microbiota genomes with third-generation sequencing. Cell Death Dis. 2021;12(6):569.PubMedPubMedCentralCrossRef
224.
Zheng W, Zhao S, Yin Y, Zhang H, Needham DM, Evans ED, et al. High-throughput, single-microbe genomics with strain resolution, applied to a human gut microbiome. Science. 2022;376(6597):eabm1483.PubMedCrossRef
225.
Poore GD, Kopylova E, Zhu Q, Carpenter C, Fraraccio S, Wandro S, et al. Microbiome analyses of blood and tissues suggest cancer diagnostic approach. Nature. 2020;579(7800):567–74.PubMedPubMedCentralCrossRef
226.
Zhou CB, Pan SY, Jin P, Deng JW, Xue JH, Ma XY, et al. Fecal signatures of Streptococcus anginosus and Streptococcus constellatus for noninvasive screening and early warning of gastric cancer. Gastroenterology. 2022;162(7):1933–1947.e18.PubMedCrossRef
227.
Zhang W, Zhou Y, Fan Y, Cao R, Xu Y, Weng Z, et al. Metal–organic-framework-based hydrogen-release platform for multieffective Helicobacter pylori targeting therapy and intestinal flora protective capabilities. Adv Mater. 2022;34(2):2105738.CrossRef
228.
Yu J, Guo Z, Yan J, Bu C, Peng C, Li C, et al. Gastric acid-responsive ROS nanogenerators for effective treatment of Helicobacter pylori infection without disrupting homeostasis of intestinal flora. Adv Sci Weinh Baden-Wurtt Ger. 2023;10(20):e2206957.
229.
Choudhury A, Ortiz PS, Young M, Mahmud MT, Stoffel RT, Greathouse KL, et al. Control of Helicobacter pylori with engineered probiotics secreting selective guided antimicrobial peptides. Microbiol Spectr. 2023;11(5):e02014–23.
Metadata
Title
Unveiling the gastric microbiota: implications for gastric carcinogenesis, immune responses, and clinical prospects
Authors
Zhiyi Liu
Dachuan Zhang
Siyu Chen
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2024
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-024-03034-7

Other articles of this Issue 1/2024

Journal of Experimental & Clinical Cancer Research 1/2024 Go to the issue

Research

METTL3 recruiting M2-type immunosuppressed macrophages by targeting m6A-SNAIL-CXCL2 axis to promote colorectal cancer pulmonary metastasis

Review

Biological mechanisms and clinical significance of endoplasmic reticulum oxidoreductase 1 alpha (ERO1α) in human cancer

Research

The localization, origin, and impact of platelets in the tumor microenvironment are tumor type-dependent

Review

Current and future therapeutic strategies for high-grade gliomas leveraging the interplay between epigenetic regulators and kinase signaling networks

Research

PELI1: key players in the oncogenic characteristics of pancreatic Cancer

Review

Liquid biopsy techniques and lung cancer: diagnosis, monitoring and evaluation
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits